El interés en corto de Contineum Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Contineum Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Contineum Therapeutics (NASDAQ:CTNM) Bolsa, Informe de interés en corto

Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics Inc

CHINA TREASURES NEW MATLS by CHINA TREASURES NEW MATLS GROUP LTD

China Treasures New Materials Group Ltd

CJS Securities analyst Larry Solow initiates coverage on BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) with a Market Outperform rating and announces Price Target of $27.

News

Price Target

Initiation

Analyst Ratings

BTSG

CJS Securities Initiates Coverage On BrightSpring Health with Market Outperform Rating, Announces Price Target of $27

Piper Sandler analyst Matt Farrell reiterates Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Overweight and maintains $40 price target.

Reiteration

MTCH

Piper Sandler Reiterates Overweight on Match Group, Maintains $40 Price Target

TD Cowen analyst Joshua Jennings maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $100 to $110.

TD Cowen Maintains Buy on Boston Scientific, Raises Price Target to $110

The U.S. defense sector is bracing for turbulence in 2025 as Goldman Sachs downgraded a key player in the industry and reiterated a bearish outlook on other defense stocks, citing risks tied to a slowing Pentagon <a href="https://www.benzinga.com/topic/donald-trump">budget and margin pressures.</a>
The defense budget, which has more than doubled over the past decade, could see deceleration — or even contraction — under the watch of Donald Trump's newly formed Department of Government Efficiency led by Elon Musk and Vivek Ramaswamy. 
"We remain cautious on defense stocks as we see decelerating and potentially negative growth in the forward U.S. Department of Defense budget," Goldman Sachs analyst Noah Poponak said in a note Thursday. 
Goldman downgraded General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) from Neutral to Sell, citing fundamental challenges across all four of its business segments.
<h1 class="wp-block-heading">Can The Defense Budget Escape DOGE Spending Cuts?</h1>
Goldman warned that defense spending may have peaked, creating "tough compares" for future growth. 
Historically, defense spending has moved in decade-long cycles, and the current high base of investment means the next phase could be one of contraction. 
Poponak also highlighted the incoming Trump administration appears eager to wind down U.S. involvement in foreign conflicts, further reducing the case for large-scale defense spending.
Poponak indicated the Pentagon's procurement efficiency as "imperfect," which could make defense spending an attractive target for cuts. Given that defense represents a significant chunk of the federal budget, trimming it may be unavoidable as DOGE seeks to deliver cost savings.
&#8220;If DOGE wants to substantially reduce total U.S. government spending, it is hard to avoid DoD,&#8221; Goldman Sachs wrote.
<h1 class="wp-block-heading">Structural Margin Pressures And Valuation Risks</h1>
Beyond the potential for lower top-line growth, defense contractors are grappling with long-term pressures on profitability. Over the past few years, the Pentagon has tightened contractual terms, effectively shifting cost risks to contractors.
"While the rate of decline may be slowing, we think margins are now structurally lower moving forward vs. the last decade," Poponak said.
DOGE could exacerbate this trend by advocating for more fixed-price contracts, even in the early stages of programs, a move that would further constrain profitability. 
Yet despite these challenges, defense stocks as a group continue to trade above their historical valuation averages. 
"Defense stocks trade above their historical average valuation level as a group, with some individual names at their high-end and a premium to the equity market," Poponak commented. 
<h1 class="wp-block-heading">Goldman Sachs Reiterates Sell Recommendations On Defense Contractors</h1>
According to Goldman Sachs, the General Dynamics downgrade reflects weaker-than-peer growth in its Technologies division, margin pressures in Marine shipbuilding, reduced supplemental funding at Combat, and delivery challenges at Gulfstream that are weighing on profitability.
"While General Dynamics trades at a discount to Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), valuation is at a level where it could derate if earnings power is disappointing the market," Poponak said.
Goldman Sachs also trimmed the 12-month price target on General Dynamics from $283 to $245. 
Lockheed Martin, often seen as the bellwether of the defense industry, also remains on the Sell list from Goldman Sachs. 
The analyst flagged risks related to the F-35 program, which has already been named as a potential target by DOGE leadership. 
"LMT currently has a large positive net pension benefit in its free cash flow, and we expect free cash to be near flat the next several years," Poponak said, adding that the company trades at 23 times estimated 2025 earnings, a steep premium for a stock facing margin and spending risks.
Northrop Grumman holds a similar Sell rating, with Goldman expressing concerns about slowing growth in its flagship B-21 bomber program. Poponak highlighted that NOC trades at 20 times the estimated 2025 earnings and warned of "incremental margin risk" ahead.
Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) is also struggling under margin pressures. Its shipbuilding business, plagued by labor shortages and cost overruns, could see profitability erode further, according to the investment bank. 
The company's recent results revealed weaker recurring margins than previously assumed, with guidance pointing to near-term margins as low as 5%, far below historical levels.
Goldman also reaffirmed its Sell ratings on L3 Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) and Mercury Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>), citing slower growth, operational risks, and valuation concerns.
<h1 class="wp-block-heading">Market Reactions</h1>
Shares of General Dynamics fell 1.01% on Thursday, while the broader industry — as tracked by the iShares U.S. Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITA#NYSE">ITA</a>) – fell 0.64%.
Lockheed Martin fell 1.52%, hitting lows last seen on July 23, 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/travel/24/12/42450095/us-airlines-set-to-fly-high-in-2025-analyst-says-perfect-storm-of-tailwinds-will-propel-industry-gains">US Airlines Set To Fly High In 2025, Analyst Says: &#8216;Perfect Storm Of Tailwinds&#8217; Will Propel Industry Gains</a></li>
</ul>
Photo: Courtesy General Dynamics

Analyst Color

Equities

Government

Large Cap

Mid Cap

Sector ETFs

Downgrades

Economics

iShares Dow Jones US Aerospace & Defense Index Fund

MRCY

Defense Stocks Face Headwinds As Trump's DOGE Targets Spending Cuts: Goldman Sachs Downgrades General Dynamics To Sell

BofA Securities analyst Michael Funk initiated coverage on Box Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/BOX/analyst-ratings" rel="noreferrer noopener">price target of&nbsp;$40</a>.
The rating implies an upside potential of 24%. As the leading enterprise data repository, Funk considers Box well positioned for AI monetization opportunities as the market transitions from simply storing data and documents to extracting value, insights, and increased productivity by leveraging AI.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42435733/taiwan-semi-founder-calls-for-new-strategy-after-intel-chiefs-departure" rel="noreferrer noopener">Taiwan Semi Founder Calls For New Strategy After Intel Chief&#8217;s Departure</a>
Moreover, enterprise headwinds (like tighter budgets and right-sized headcount) are fading, yet valuation at 13.4 times Street calendar 2025 free cash flow still reflects an overly bearish view of revenue growth and margin expansion potential given a raft of new product offerings (Box AI Studio, Workflow, Security and Box Doc Gen).
Funk estimates Box&#8217;s Intelligent Content Management (ICM) portfolio will expand the company&#8217;s addressable market to $26 billion. This market is projected to grow at a 13% CAGR through 2028. While this arena is fragmented and includes several large firms, Funk noted Box can carve out a substantial niche based on its entrenched position as an enterprise data repository and compelling AI product roadmap. 
Further, he said the 2024-2027 consensus revenue CAGR of 6.7% (versus BofA at 7.3%) and his growth versus maintenance valuation analysis signals an overly pessimistic view of ICM.
The price target implies a 2025 EV/FCF multiple of 15 times Funk&#8217;s above-street estimate. That compares with the average of 21 times for low-growth software peers and collaboration peers, at a median of 24 times.
Funk projected fourth-quarter revenue of $279.97 million and adjusted EPS of $0.46.
Price Action: BOX stock is up 1.81% at $32.86 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42434183/photronics-q4-earnings-beats-expectations-ceo-credits-strong-us-sales-2025-backed-by-ai-edge-computing-and-supply-chain-trends" target="_blank" rel="noreferrer noopener">Photronics Q4 Earnings: Beats Expectations, CEO Credits Strong US Sales, 2025 Backed By AI, Edge Computing, And Supply Chain Trends</a></li>
</ul>
Photo via Shutterstock.

Trading Ideas

Box Undervalued? Analyst Flags Overly Pessimistic Views Amid AI Monetization Push

CIBC maintains RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) with a Outperformer and raises the price target from $102 to $109.

CIBC Maintains Outperformer on RB Global, Raises Price Target to $109

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $163 price target.

JAZZ

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Maintains $163 Price Target

TD Cowen analyst John Blackledge maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $240 to $265.

AMZN

TD Cowen Maintains Buy on Amazon.com, Raises Price Target to $265

On Thursday, Palisade Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Palisade Bio priced an underwritten public offering for gross proceeds of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42466940/palisade-bio-announces-pricing-of-5-million-underwritten-public-offering-priced-at-market-under-na" rel="noreferrer noopener">approximately $5 million</a>.
The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249.
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.
The company will use the net proceeds primarily to fund the Phase 1 trial of PALI-2108, pre-clinical studies, research and development, and working capital.
Last week, Palisade Bio revealed preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human study for PALI-2108 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42289096/palisade-bio-announces-preliminary-data-from-phase-1-clinical-study-of-pali-2108-for-the-treatment" rel="noreferrer noopener">for Ulcerative Colitis</a>.
Preliminary results appear to indicate that PALI-2108 was safe and well tolerated in the first three cohorts (n=24; 6:2 active to placebo) at 15mg, 50mg, and 150mg, with no treatment-related dose reductions, no Treatment-Related Adverse Events (TRAEs), no Serious Adverse Events (SAEs), and no treatment-related lab abnormalities in any subject.
Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting PALI-2108 is performing as designed with colonic bioactivation.
Based on the findings with this preliminary safety data, the company is advancing toward its planned crossover study to evaluate the effects of food on pharmacokinetics, followed by multiple ascending dose (MAD) cohorts and, finally, a multiple-dose cohort of patients with Ulcerative Colitis.
The company is on track to report topline data from this study in the first half of 2025.
As of September 30, the company had cash and cash equivalents of $8.0 million. The company believes it has sufficient cash to fund its planned operations through the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41900382/palisade-bio-reports-third-quarter-2024-financial-results-and-outlines-key-accomplishments-and-nex" rel="noreferrer noopener">first quarter of 2025</a>.
Price Action: PALI stock is trading 51.5% higher at $2.12 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42459145/3d-systems-agrees-to-sell-geomagic-portfolio-for-123-million-ai-and-3d-printing-take-center-stage" target="_blank" rel="noreferrer noopener">3D Systems Agrees To Sell Geomagic Portfolio For $123 Million, AI And 3D Printing Take Center Stage</a></li>
</ul>

Biotech

Health Care

Financing

Offerings

Movers

General

PALI

What's Going On With Palisade Bio Stock On Thursday?

WIIM

TORO

Toro shares are trading higher after the company announced it entered into a Share Purchase Agreement with MPC Münchmeyer Petersen & Co. GmbH for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Münchmeyer Petersen Capital AG.

Stifel analyst Patrick Ho reiterates Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and maintains $105 price target.

CAMT

Stifel Reiterates Buy on Camtek, Maintains $105 Price Target

HC Wainwright &amp; Co. analyst Oren Livnat maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and raises the price target from $6 to $7.5.

TRVI

HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $7.5

Loop Capital analyst Alton Stump maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Buy and lowers the price target from $59 to $45.

PLAY

Loop Capital Maintains Buy on Dave & Buster's Enter, Lowers Price Target to $45

BTIG analyst Julian Harrison downgrades Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) from Buy to Neutral.

KROS

BTIG Downgrades Keros Therapeutics to Neutral

Loop Capital analyst Anthony Chukumba maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Hold and raises the price target from $265 to $290.

TSCO

Loop Capital Maintains Hold on Tractor Supply, Raises Price Target to $290

IPOs

TTAN

ServiceTitan Shares Open For Trade At $101/Share; IPO Priced At $71/Share On 8.8M Shares

Loop Capital analyst Laura Champine maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Hold and lowers the price target from $35 to $30.

Loop Capital Maintains Hold on Match Group, Lowers Price Target to $30

Streaming Destination for HBO, Warner Bros. Pictures, the DC Universe, A24, ID and More Now Available to All Spectrum TV Select Customers at No Extra Cost
STAMFORD, Conn. and NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Spectrum and Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) today announced that WBD's premium streaming service Max is now available to all of Spectrum's TV Select video customers at no additional cost, as part of the two companies' new distribution agreement. Spectrum TV Select customers will receive Max With Ads, which retails for $9.99 per month and includes must-see entertainment from brands such as HBO, Warner Bros., Max Originals, DC, Harry Potter, as well as iconic shows like "Friends" and "The Big Bang Theory."

CHTR

Spectrum And Warner Bros. Discovery Announce WBD's Streaming Service Max Is Now Available To All Of Spectrum's TV Select Video Customers At No Additional Cost, As Part Of The Two Companies' New Distribution Agreement

BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Buy and raises the price target from $87 to $91.

GMED

BTIG Maintains Buy on Globus Medical, Raises Price Target to $91

European pharma service provider Lonza Group Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGY#OTC">LZAGY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGF#OTC">LZAGF</a>) announced plans to exit its Capsules &amp; Health Ingredients (CHI) business.
Full implementation is expected by second quarter of 2025.
The decision coincides with the company&#8217;s strategy to focus on contract development and manufacturing organization (CDMO). Lonza expects EBITDA margins exceeding 30% for its CDMO segment beyond 2025.
William Blair writes that the decision to divest its CHI business and reorganize the CDMO business &#8220;rids Lonza of the main drag&#8221; and &#8220;creates a much cleaner and more compelling pure-play CDMO story.&#8221;
The new structure aims to simplify operations by transitioning from three divisions and nine business units to three integrated business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
The Integrated Biologics platform will consolidate Mammalian and Drug Product Services, while Advanced Synthesis merges hybrid chemistry and biology solutions, incorporating the Small Molecules division and Bioconjugates.
Specialized Modalities will be focused on cell and gene therapies, mRNA, and microbial solutions.
2024 and Beyond: Growth Outlook
<ul>
<li>Lonza maintained its 2024 guidance of flat constant exchange rate (CER) sales growth and a CORE EBITDA margin between 27% and 29%, with CDMO performance offsetting softness in the CHI segment.</li>
<li>For 2025, Lonza projects CER sales growth approaching 20%, supported by the acquisition of the Vacaville site and organic growth in the low teens.</li>
<li>Beyond 2025, the company anticipates low-teen percentage CER sales growth.</li>
<li>For CHI, Lonza expects modest growth and a gradual return to higher margins post-2025.</li>
<li>Lonza reaffirmed its commitment to a dividend policy with a payout ratio of 35-45%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>

LZAGF

LZAGY

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Repor...

Morgan Stanley Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics GAAP EPS of -$0.39

IPO Roundup: FrontView REIT, StandardAero and more

Joel Beatty, an analyst from Robert W. Baird, has initiated a new Buy rating on Contineum Therapeutics, Inc. Class A (CTNM). Joel Beatty's rating i...

Promising Prospects and Strong Financials Bolster Buy Rating for Contineum Therapeutics

Baird initiated coverage of Contineum (CTNM) with an Outperform rating and $32 price target Contineum is an early clinical stage biotech company de...

Contineum initiated with an Outperform at Baird

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) today and set a price...

Stifel Nicolaus Reaffirms Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

"The third quarter of 2024 was focused on clinical execution for our lead assets PIPE-307 and PIPE-791, where we have multiple potential opportunit...

Contineum reports Q3 EPS (40c), consensus (41c)

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from Stifel Nicolaus

Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pa...

Contineum announces FDA authorization for PIPE-791

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has released its Q3 earnings. Here is a breakdown of the information Contineum Therapeutics, Inc. ...

Contineum Therapeutics: Q3 2024 Financial Overview

ACTHF

APUS

BIOA

CHARU

CTNM

CUPR

FBGL

GRDN

HUHU

MAMO

PTLE

SARO

SNYRD

SUNH

TLIH

TMGX

ZBAO

Press Releases

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Comments

Contineum Therapeutics

Interés en corto

Contineum Therapeutics (NASDAQ:CTNM) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL